Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Status:
RECRUITING

Trial end date:
2030-02-01

Target enrollment:

Participant gender:

maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days

PHASE2

Technische Universitt Dresden

ivosidenib
Magnesium